PhagoMed becomes BioNTech R&D (Austria)

In October 2021, BioNTech expanded its infectious disease portfolio capabilities by acquiring PhagoMed Biopharma GmbH, an Austrian biotechnology company, specialized in the development of a new class of antibacterials.

PhagoMed announced that it has been acquired by BioNTech SE, becoming BioNTech R&D (Austria). This enables it to accelerate its development programmes to fight antimicrobial resistance. Alexander Belcredi and Lorenzo Corsini will remain as Managing Directors, with the team set to further expand.

Read more